Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: Potential diagnostic implications

Journal of Hypertension

Volumn 27, Issue 2, 2009, Pages 418-424

  López, Begoña ^a   González, Arantxa ^a   Querejeta, Ramón ^b   Barba, Joaquín ^c   Díez, Javier ^a,c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Aminoterminal probrain natriuretic peptide; Biomarkers; Cardiotrophin 1; Heart failure; Hypertension

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; CALCIUM ANTAGONIST; CARDIOTROPHIN 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; BRAIN NATRIURETIC PEPTIDE; CYTOKINE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; CYTOKINE PRODUCTION; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HEART HYPERTROPHY; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ROC CURVE; AGED; BLOOD; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED;

AGED; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; ROC CURVE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 63849213906     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32831ac981     Document Type: Article

References (30)

1. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 1996; 2:243-249.
2. Pennica D, King KL, Shaw KJ, Luis E, Rullamas J, Luoh SM, et al. Expression cloning of cardiotrophin-1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci USA 1995; 92:1142-1146.
3. Sheng Z, Pennica D, Wood WI, Chien KR. Cardiotrophin-1 displays early expression in the murine heart tube and promotes cardiac myocyte survival. Development 1996; 122:419-428.
4. Lo' pez N, DI'ez J, Fortuño MA. Differential hypertrophic effects of cardiotrophin-1 on adult cardiomyocytes from normotensive and spontaneously hypertensive rats. J Mol Cell Cardiol 2006; 41:902-913.
5. Lo' pez N, Varo N, DI'ez J, Fortuño MA. Loss of myocardial LIF receptor in experimental heart failure reduces cardiotrophin-1 cytoprotection. A role for neurohumoral agonists? Cardiovasc Res 2007; 75:536-545.
6. Lo' pez B, Gonza' lez A, Lasarte JJ, Sarobe P, Borra's F,DI'az A, et al. Is plasma cardiotrophin-1 a marker of hypertensive heart disease? J Hypertens 2005; 23:625-632.
7. Pemberton CJ, Raudsepp SD, Yandle TG, Cameron VA, Richards AM. Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch. Cardiovasc Res 2005; 68:109-117.
8. Gonza' lez A, Lo' pez B, Martin-Raymondi D, Lozano E, Varo N, Barba J, et al. Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. J Hypertens 2005; 23:2297-2304.
9. Lo' pez B, Castellano JM, Gonza' lez A, Barba J, DI'ez J. Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension. Hypertension 2007; 50:977-983.
10. Gonza' lez A, Ravassa S, Loperena I, Lo' pez B, Beaumont J, Querejeta R, et al. Association of depressed cardiac gp130-mediated antiapoptotic pathways with stimulated cardiomyocyte apoptosis in hypertensive patients with heart failure. J Hypertens 2007; 25:2148-2157.
11. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: Executive Summary and Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the evaluation and management of heart failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation 2001; 104:2996-3007.
12. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure. The Framingham Study. J Am Coll Cardiol 1993; 22:6A-13A.
13. Querejeta R, Varo N, Lo' pez B, Larman M, Artiñano E, Etayo JC, et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000; 101:1729-1735.
14. Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992; 19:1550-1558.
15. Schillaci G, Pasqualini L, Verdecchia P, Vaudo G, Marchesi S, Porcellati C, et al. Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol 2002; 39:2005-2011.
16. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7:79-108.
17. Aukrust P, Ueland T, Lien E, Bendtzen K, Mü ller F, Andreassen AK, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999; 83:376-382.
18. Talwar S, Squire IB, Downie PF, O'Brien RJ, Daview JE, Ng LL. Elevated circulating cardiotrophin-1in heart failure: relationship with parameters of left ventricular systolic dysfunction. Clin Sci 2000; 99:83-88.
19. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, et al. Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. J Am Coll Cardiol 2001; 38:1485-1490.
20. Asai S, Saito Y, Kuwahara K, Mizuno Y, Yoshimura M, Higashikubo C, et al. The heart is a source of circulating cardiotrophin-1 in humans. Biochem Biophys Res Commun 2000; 279:320-323.
21. Hishinuma S, Funamoto M, Fujio Y, Kunisada K, Yamauchi-Takihara K. Hypoxic stress induces cardiotrophin-1 expression in cardiac myocytes. Biochem Biophys Res Commun 1999; 264:436-440.
22. Sano M, Fukuda K, Kodama H, Pan J, Saito M, Matsuzaki J, et al. Interleukin- 6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. J Biol Chem 2000; 275:29717-29723.
23. Lo' pez-Andre's N, Iñ igo C, Gallego I, DI'ez J, Fortuño MA. Aldosterone induces n-1 expression in HL-1 adult cardiomyocytes. Endocrinology 2008; 149:4970-4978.
24. Nicol RL, Frey N, Pearson G, Cobb M, Richardson J, Olson EN. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J 2001; 11:2757-2767.
25. Zolk O, Engmann S, Mü nzel F, Krajcik R. Chronic cardiotrophin-1 stimulation impairs contractile function in reconstituted heart tissue. Am J Physiol Endocrinol Metab 2005; 288:E1214-E1221.
26. Zolk O, Ng LL, O'Brien RJ, Weyand M, Eschenhagen T. Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished gp130 receptor protein abundance. Circulation 2002; 106:1442-1446.
27. Khan SQ, Kelly D, Quinn P, Davies JE, Ng LL. Cardiotrophin-1 predicts death or heart failure following acute myocardial infarction. J Card Fail 2006; 12:635-640.
28. Tsutamoto T, Asai S, Tanaka T, Sakai H, Nishiyama K, Fujii M, et al. Plasma level of cardiotrophin-1 as a prognostic predictor in patients with chronic heart failure. Eur J Heart Fail 2007; 9:1032-1037.
29. Lo' pez N, DI'ez J, Fortuño MA. Characterization of the protective effects of cardiotrophin-1 against nonischemic death stimuli in adult cardiomyocytes. Cytokine 2005; 30:282-292.
30. Ghosh S, Ng LL, Talwar S, Squire IB, Galinanes M. Cardiotrophin-1 protects the human myocardium from ischemic injury. Comparison with the first and second window of protection by ischemic preconditioning. Cardiovasc Res 2000; 48:440-447.